Survodutide, a once weekly subcutaneous dual glucagon–GLP-1 agonist, was examined in a large, multicenter, phase IIb trial in patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis (22). Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.